Development of a Highly Sensitive Bioanalytical Assay for the Quantification of Favipiravir

Overview

Journal bioRxiv

Date 2021 Feb 10

PMID 33564761

Authors

Paul Curley

Megan Neary

Usman Arshad

Lee Tatham

Henry Pertinez

Helen Box

Rajith Kr Rajoli

Anthony Valentijn

Joanne Sharp

Steve P Rannard

Andrew Owen

Affiliations

Soon will be listed here.

Abstract

Favipiravir (FAV; T-705) has been approved for use as an anti-influenza therapeutic and has reports against a wide range of viruses (e.g., Ebola virus, rabies and norovirus). Most recently FAV has been reported to demonstrate activity against SARS-CoV-2. Repurposing opportunities have been intensively studied with only limited success to date. If successful, repurposing will allow interventions to become more rapidly available than development of new chemical entities. Pre-clinical and clinical investigations of FAV require robust, reproducible and sensitive bioanalytical assay. Here, a liquid chromatography tandem mass spectrometry assay is presented which was linear from 0.78-200 ng/mL Accuracy and precision ranged between 89% and 110%, 101% and 106%, respectively. The presented assay here has applications in both pre-clinical and clinical research and may be used to facilitate further investigations into the application of FAV against SARS-CoV-2.

References

Zhou W, Yang S, Wang P . Matrix effects and application of matrix effect factor. Bioanalysis. 2017; 9(23):1839-1844. DOI: 10.4155/bio-2017-0214. View

Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S . Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014; 105:17-21. DOI: 10.1016/j.antiviral.2014.02.014. View

Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Mai Le Q . T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 2010; 107(2):882-7. PMC: 2818889. DOI: 10.1073/pnas.0909603107. View

Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Soyinka J . Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J Antimicrob Chemother. 2014; 70(2):555-61. PMC: 6538536. DOI: 10.1093/jac/dku420. View

Kaptein S, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L . Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020; 117(43):26955-26965. PMC: 7604414. DOI: 10.1073/pnas.2014441117. View

Smee D, Hurst B, Egawa H, Takahashi K, Kadota T, Furuta Y . Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 2009; 64(4):741-6. PMC: 2740635. DOI: 10.1093/jac/dkp274. View

Nguyen T, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet A . Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017; 11(2):e0005389. PMC: 5340401. DOI: 10.1371/journal.pntd.0005389. View

Wang G, Wan J, Hu Y, Wu X, Prhavc M, Dyatkina N . Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues. J Med Chem. 2016; 59(10):4611-24. DOI: 10.1021/acs.jmedchem.5b01933. View

Westover J, Sefing E, Bailey K, Van Wettere A, Jung K, Dagley A . Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res. 2015; 126:62-8. PMC: 4724333. DOI: 10.1016/j.antiviral.2015.12.006. View

10.

Delang L, Abdelnabi R, Neyts J . Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85-94. DOI: 10.1016/j.antiviral.2018.03.003. View

11.

Ison M, Scheetz M . Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. EBioMedicine. 2021; 63:103204. PMC: 7785424. DOI: 10.1016/j.ebiom.2020.103204. View

12.

Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S . Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis. 2014; 8(5):e2804. PMC: 4006714. DOI: 10.1371/journal.pntd.0002804. View

13.

Smither S, Eastaugh L, Steward J, Nelson M, Lenk R, Lever M . Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014; 104:153-5. DOI: 10.1016/j.antiviral.2014.01.012. View

14.

Pires de Mello C, Tao X, Kim T, Vicchiarelli M, Bulitta J, Kaushik A . Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125552. DOI: 10.1128/AAC.00967-18. View

15.

Arshad U, Pertinez H, Box H, Tatham L, Rajoli R, Curley P . Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020; 108(4):775-790. PMC: 7280633. DOI: 10.1002/cpt.1909. View

16.

Shiraki K, Daikoku T . Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209:107512. PMC: 7102570. DOI: 10.1016/j.pharmthera.2020.107512. View

17.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

18.

Azuma T, Ishida M, Hisamatsu K, Yunoki A, Otomo K, Kunitou M . Fate of new three anti-influenza drugs and one prodrug in the water environment. Chemosphere. 2016; 169:550-557. DOI: 10.1016/j.chemosphere.2016.11.102. View

19.

Furuta Y, Gowen B, Takahashi K, Shiraki K, Smee D, Barnard D . Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100(2):446-54. PMC: 3880838. DOI: 10.1016/j.antiviral.2013.09.015. View

20.

Gowen B, Juelich T, Sefing E, Brasel T, Smith J, Zhang L . Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis. 2014; 7(12):e2614. PMC: 3873268. DOI: 10.1371/journal.pntd.0002614. View